Amendments to the Claims:

Please amend claims 42-45 as shown in the listing of claims. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-24. (Canceled)

25. (Previously Presented) A compound according to the formula IA:



IA

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

D is absent or selected from the group consisting of

(1) substituted or unsubstituted C_3-C_8-cycloalkyl;

(2) substituted or unsubstituted aryl;

(3) substituted or unsubstituted heterocyclyl; and

(4) substituted or unsubstituted heteroaryl;

Y is selected from the group consisting of

(1) substituted or unsubstituted C_3-C_8-cycloalkyl;

(2) substituted or unsubstituted aryl;

(3) substituted or unsubstituted heterocyclyl; and

(4) substituted or unsubstituted heteroaryl;

R_4 is H or substituted or unsubstituted C_1-C_6-alkyl;

A is selected from the group consisting of

(1) $-C(R^{1a},R^{2a})OR^{3a}$; and

(2) $-C(R^{1a},R^{2a})N(R^{4a},R^{5a})$;

wherein R^{1a}, R^{2a}, R^{3a}, R^{4a}, and R^{5a} are independently selected from the group consisting of

(1) H; and

(2) substituted and unsubstituted C_1-C_6-alkyl.

26. (Previously Presented) The compound of claim 25, wherein A is $-C(R^{1a},R^{2a})OR^{3a}$.

27. (Previously Presented) The compound of claim 26, wherein A is $-CH_2OH$.

28. (Previously Presented) The compound of claim 26, wherein A is $-CH(CH_3)OH$.

29. (Previously Presented) The compound of claim 25, wherein A is $-C(R^{1a},R^{2a})N(R^{4a},R^{5a})$.

30. (Previously Presented) The compound of claim 29, wherein A is $-CH_2NH_2$.

31. (Previously Presented) The compound of claim 29, wherein A is $-CH(CH_3)NH_2$.

32. (Previously Presented) The compound of claim 25, wherein D is absent and Y is a substituted or unsubstituted aryl.

33. (Previously Presented) The compound of claim 25, wherein D is a substituted or unsubstituted aryl and Y is a substituted or unsubstituted aryl.

34. (Currently Amended) A compound according to the formula IB:



IB

or a stereoisomer, pharmaceutically acceptable salt, ester, or prodrug thereof, wherein

D is absent or selected from the group consisting of

(1) substituted or unsubstituted C_3-C_8-cycloalkyl;

(2) substituted or unsubstituted aryl;

(3) substituted or unsubstituted heterocyclyl; and

(4) substituted or unsubstituted heteroaryl;

G ~~is absent or~~ is –C≡C-C≡C–;

Y is selected from the group consisting of

(1) substituted or unsubstituted C_3-C_8-cycloalkyl;

(2) substituted or unsubstituted aryl;

(3) substituted or unsubstituted heterocyclyl; and

(4) substituted or unsubstituted heteroaryl;

R_4 is H or substituted or unsubstituted C_1-C_6-alkyl;

A is ~~selected from the group consisting of~~

~~(1) –C(R^{1a},R^{2a})OR^{3a}; and~~

~~(2)~~ –C(R^{1a},R^{2a})N(R^{4a},R^{5a});

wherein R^{1a}, R^{2a}, R^{3a}, R^{4a}, and R^{5a} are independently selected from the group consisting of

(1) H; and

(2) substituted and unsubstituted C_1-C_6-alkyl.

35. (Currently Amended) A compound ~~of claim 34~~ according to Formula VIII:



VIII

or stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein

E is absent or selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl, and

(5) substituted or unsubstituted heteroaryl,

or E and R^{3L}, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R^{1L}, R^{3L} are independently selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 7 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

36. (Previously Presented) A compound of claim 34 according to Formula IX:



IX

or stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein

E is absent or selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl, and

(5) substituted or unsubstituted heteroaryl,

or E and R^{3L}, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R^{1L}, R^{3L} are independently selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 7 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

37. (Previously Presented) A compound of claim 34 according to Formula X:



X

or stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof, wherein

E is absent or selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) substituted or unsubstituted aryl,

(4) substituted or unsubstituted heterocyclyl, and

(5) substituted or unsubstituted heteroaryl,

or E and R^{3L}, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 10 ring atoms, wherein 1-4 ring atoms of the heterocyclic ring system are selected from N, O and S;

R^{1L}, R^{3L} are independently selected from the group consisting of

(1) H,

(2) substituted or unsubstituted C_1-C_6-alkyl,

(3) C_1-C_6-alkyl substituted with aryl,

(4) C_1-C_6-alkyl substituted with heterocyclyl, and

(5) C_1-C_6-alkyl substituted with heteroaryl,

or R^{1L} and R^{3L}, together with the atoms to which they are attached form a substituted or unsubstituted heterocyclic ring, having from 5 to 7 ring atoms, wherein 1-2 ring atoms of the heterocyclic ring system are selected from N, O and S.

38. (Previously Presented) A pharmaceutical composition comprising the compound of claim 25 and a pharmaceutically acceptable excipient.

39. (Previously Presented) A pharmaceutical composition comprising the compound of claim 34 and a pharmaceutically acceptable excipient.

40. (Previously Presented) A pharmaceutical composition comprising a compound of claim 25, a second agent, and a pharmaceutically acceptable excipient, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

41. (Previously Presented) A pharmaceutical composition comprising a compound of claim 34, a second agent, and a pharmaceutically acceptable excipient, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

42. (Currently Amended) A method of **inhibiting LpxC**~~**treating a patient**~~ comprising administering to a patient in need thereof, an effective amount of the compound of claim 25.

43. (Currently Amended) A method of **inhibiting LpxC**~~**treating a patient**~~ comprising administering to a patient in need thereof, an effective amount of the compound of claim 34.

44. (Currently Amended) A method of **inhibiting LpxC**~~**treating patient**~~ comprising administering to a patient in need thereof, an effective amount of the compound of claim 25 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

45. Currently Amended) A method of **inhibiting LpxC**~~**treating patient**~~ comprising administering to a patient in need thereof, an effective amount of the compound of claim 34 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

46. (Previously Presented) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of claim 25.

47. (Previously Presented) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of claim 34.

48. (Previously Presented) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of claim 25 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.

49. (Previously Presented) A method of treating an infection comprising administering to a patient in need thereof, an effective amount of the compound of claim 34 and an effective amount of a second agent, wherein the second agent is an antibacterial agent, an antiendotoxin agent, or an inhaled non-antibacterial agent for the treatment of respiratory tract infection.